focu start
ultim believ busi fundament appear solid look
guidanc messag consist
compani
pre-announce focu earn expect
revenu ramp throughout ration think make sens could
weigh sentiment near term quarter consist compani
pre-announc strength area matter thesi notabl
compani post record instrument sale y/i consum
despit difficult comp impact prior quarter stock compani
continu see multi-year upgrad cycl ahead novaseq note
hiseq custom upgrad new platform far weak point
earn adjust ep report
came model weaker gross margin higher instrument mix
combin greater expect oper expens invest drove
differ partial off-set lower-than-anticip tax rate
turn expect consist prior guidanc
revenu growth view revenu guidanc potenti conserv
start year given traction novaseq said depend pace
ramp-up popul sequenc initi view time
debat given fund infrastructur put place around program
world-wide adj ep forecast repres growth
y/i guidanc exclud dilut pacbio model given
acquisit yet complet estim transact could dilut
assum mid-year close altogeth dilut
overal continu see substanti underli momentum around adopt
across clinic research set believ uniqu
posit address given reput scale valu proposit reiter
overview rate
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight leader next
gener sequenc project
signific growth driven larg research studi
nascent opportun clinic diagnost
signific competit moat rel
competit given brand scale
growth forseeabl futur
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ep
growth ultim depend
custom fund includ govern grant
nih well clinic reimburs lower
downsid case reflect downsid
ep
ultim believ busi fundament appear solid look
guidanc messag consist compani pre-announce
focu earn expect revenu ramp
throughout ration think make sens could weigh sentiment
near term quarter consist compani pre-announc
strength area matter thesi notabl compani post record
instrument sale y/i consum despit difficult comp
impact prior quarter stock compani continu see multi-year upgrad cycl
ahead novaseq note hiseq custom upgrad
new platform far weak point earn adjust ep
report came model weaker gross margin
higher instrument mix combin greater expect oper expens
invest drove differ partial off-set lower-than-anticip tax
turn expect consist prior guidanc
revenu growth view revenu guidanc potenti conserv start
year given traction novaseq said depend pace ramp-up
popul sequenc initi view time debat given fund
infrastructur put place around program world-wide adj
ep forecast repres growth y/i guidanc exclud
dilut pacbio model given acquisit yet complet
estim transact could dilut assum mid-year close
altogeth dilut overal continu see substanti
underli momentum around adopt across clinic research set
believ uniqu posit address given reput scale
valu proposit reiter overview rate
histor valuat price earn yr earn growth compound-annual-growth-rate
believ initi guidanc repres conserv start
compani expect growth y/i impli revenu billion
embed revenu guidanc fx headwind embed guidanc mid-
teen sequenc revenu sequenc consum growth manag
echo cautiou view consum genet test expect array revenu
deceler low-single-digit growth anticip mid-single-digit growth
sequenc system novaseq shipment like flat-to-slightli gross
margin expect slightli given greater contribut lower-margin
popul genom initi oncolog collabor oper expens
anticip slightli tax rate expect
ep expect rang touch estim
upper end includ ep guidanc helix dilut keep mind believ
pacbio transact dilut base mid-year close dilut
yet embed estim
revenu expect sequenti sequenc system revenu
declin roughli q/q altern sequenc consum expect
flat slightli q/q sequenc servic revenu flat microarray
revenu expect grow sequenti mid-to-high singl digit gross margin
anticip slightli sequenti due favor mix partial off-set higher
array servic revenu oper expens expect flat expect
tax rate meaning lower full year guidanc due one-
time benefit final guid meaning chang share count q/q
initi guidanc modestli lower initi
expect note good track record recent year deliv
guidanc growth gross op base per sharenon-gaap interest extinguish debtleg contingenciescost-method investmentsconting compensationheadquart relocationothergaap slightli barclay illumina inc
upsid target look back beaten initi revenu
forecast year ep forecast year averag revenu upsid around
translat ep upsid versu initi guidanc addit year
revenu outperform initi guidanc averag beat revenu
ep
track record actual result vs initi guidanc
note adj ep current forecast revenu actual provid present
note place roughli cumul novaseq platform
end includ placement
impli placement fell modestli short guidanc call
placement ceo franci desouza describ miss time dynam
compani continu see strong demand platform field
compani custom base current adopt novaseq drive adopt
broader rang custom announc sever chang lower-
throughput flow cell strategi novaseq compani decreas price
flow cell respect combin launch prime
sp flow cell compani hope catalyz placement lower throughput
hiseq custom continu confid novaseq expand whole-
genom sequenc market note novaseq custom new high
throughput sequenc sequenc whole compani still believ
novaseq upgrad cycl span multipl year approxim high
throughput custom yet adopt novaseq
model estim place novaseq placement
averag consum pull-through follow expect
placement assum novaseq place repres
replac least one hiseq compani start see cannib hiseq
 custom well given rel advantag novaseq forecast
billion novaseq revenu year launch compar million
nextseq revenu million hiseq revenu year launch
assumpt model place novaseq per year hiseq
hiseq decommiss persist beyond given multi-year adopt util
increas per novaseq end model million
survey averag sinc assum new custom add lower overal average
barclay research revenu build
pleas see survey
say elast
upgrad ow
remind survey march-april show signific
demand novaseq continu expect major custom transit toward
platform custom spoke broadli expect de-commiss
hiseq hiseq instal base novaseq addit replac least
instrument across board shown novaseq instal base custom
spoke expect doubl today next year
expect lead signific reduct hiseq instrument
segmentarray y/i miniseq instal y/i y/i stack y/i product y/i instrument instrument instrument instrument instrument miniseq instrument y/i y/i product product y/i product y/i servic y/i y/i consum instrument barclay illumina inc
hiseq instrument collect decreas one custom transit
fleet nextseq onto novaseq instrument interestingli speak one
custom alreadi sold two novaseq anoth lab made
strateg pivot focu bioinformat cater custom buy novaseq
proprietari novaseq custom survey show major transit toward novaseq platform
custom survey expect weight averag budget increas
custom expect budget declin next year broad
rang expect growth matur center project growth
rapidli grow sequenc custom project growth one smaller
research custom cite flat budget use novaseq cost save drive offset
amount volum coverag driver sequenc growth almost everi
custom use depth everi custom expect spend least million per
year consum novaseq weight averag million
believ unlik actual attain level overal instal base
averag sinc new custom addit drag overal novaseq averag
model project million novaseq util per instrument end
result self report back envelop math suggest
decent approxim compar net instrument add decommiss
project novaseq util would suggest custom survey
increas consum spend gb sequenc
estim custom proprietari novaseq survey increas sequenc spend
revenu grew y/i million million expect
follow pre-announc overal post better-than-expect demand
instrument geograph perspect growth broad base
quarter growth unit state growth emea growth
asia-pacif region growth china exclud tariff stock
growth china would result emea benefit sequenc
program genom england
utilizationrev mmpull-through per inst per gbinstal base revsgb seq mm instal base revsgb seq mm revsgb yeary/i chang barclay illumina inc
revenu y/i growth
continu believ china long-term structur growth driver
life scienc research sequenc fit natur countri ambit tackl
long-term societ need transit industri economi servic
economi better compet market china repres
revenu dwarf larger economi like unit state
europ said market experienc signific growth
believ market sustain growth
next sever year eclips billion revenu
expect china drive substanti growth number year
revenu increas y/i million total revenu
consum grew quarter strength across low medium high
throughput analyz adjust time stock order consum
grew quarter note novaseq consum revenu larger
versu major revenu come flow cell custom
nextseq util came high end guid rang
miseq miniseq util fell within guidanc rang
respect given on-going novaseq upgrad cycl hiseq consum revenu
continu declin y/i instrument revenu increas y/i servic
revenu also strong quarter grow y/i
novaseq high-throughput sequenc platform custom focus
whole-genom sequenc advantag rel legaci hiseq hiseq
product line instal base around hiseq hiseq instrument
compani address larg market opportun base instrument sale alon
upsid would driven market expans drive higher consum
revenu said placement cannib exist instrument consum
opportun would limit note consum cost per sampl
like go applic mean consum revenu could
actual declin per-box basi view launch make sens
revolutionari product aim drive replac cycl put rest
concern around revenu visibl near term longer term overcapac
concern like remain compani tri expand market beyond
design system larg market opportun mind note
system allow highest-throughput achiev lower sequenc cost
much lower capit commit rel hiseq hiseq
compani believ architectur novaseq platform eventu
allow achiev genom system use newli develop
company/systemlaunchedinstru costrun costrun lengthrun speedthroughputpric per gbilluminaiseq fisher life ion day all-in n/an/abgi complet genomicsrevoloc ii long nanopor barclay illumina inc
flow cell allow higher-throughput increas speed-to-result
maintain accuraci earlier system compani launch novaseq
four flow cell option prime sp four flow cell
throughout capabl tb hiseq respect
modestli reduc speed-to-result hiseq day day
novaseq price capabl run three flow cell
earn announc cancel novaseq
flow cell custom primarili demand novaseq instrument
hiseq anticip demand hiseq weaker quarter custom
opt novaseq platform importantli focus convert
exist hiseq custom novaseq remind hiseq launch
per system januari announc launch
hiseq enhanc leverag capabl hiseq
system hiseq price reagent price per gb
similarli hiseq price provid half output lower
reagent costs/fast run time base commentari assum util
low end compani guid rang per instrument
hiseq consum expect trend downward throughout beyond
hiseq launch novaseq plan drive replac cycl
hiseq custom come year launch hiseq
sequenc whole human genom compani market product
 sell ten instrument increas throughput larg genom center
reach covet genom price system million
note hiseq consum revenu continu steadi declin
project transit novaseq expect signific replac cycl
instrument follow recent launch flow cell said
compani note number custom need finish current project
januari announc sell hiseq five system
configur known hiseq hiseq allow product center
adopt high-throughput whole genom sequenc lower capit invest
 full util set-up estim sequenc
genom year compani sell hiseq system million
addit hiseq xs million thereaft sequenc cost per gb
approxim versu hiseq
nextseq launch nextseq system fill nich product
portfolio hiseq miseq instrument product flex whole
human genom sequenc target panel price per system
estim compani place nextseq global pull-through
high end guid rang
also launch nextseq combin microarray scan
nextseq sequenc system initi array qualifi system
cytogenet pgd applic expect enabl broad rang
applic reproduct health genet health oncolog adapt
allow lab gain access array sequenc singl capital-expenditure
miseq miseq util fell within compani guid rang quarter sinc
launch miniseq encourag lower-than-expect level
miseq cannib ultim believ market desktop
instrument minimum estim place though
could make argument market size product price
unit expect annual pull-through
miniseq/iseq launch januari miniseq compani smallest
benchtop sequenc design target sequenc applic smaller lab
cost instrument roughli pull number quarter
rang model current instal base miniseq iseq
instrument earli januari announc iseq launch
expand portfolio breadth lower-throughput end sequenc
market compani describ iseq inexpens fast easi use sequenc
iseq target address market potenti custom rang
current owner new-to- custom iseq gener million
read greater per run run-tim rang hour price
per sampl rang addit sequenc cost less
instal custom less one hour shipment iseq
began end note alreadi place
array revenu increas y/i quarter million strength driven
primarili instrument consum respect servic
revenu declin quarter due consum test weak array
servic revenu expect declin sequenti addit compani
anticip slowdown array growth remind provid in-hous
test servic dtc test compani notabl ancestrydna compani also
supplier dtc compani run volum in-hous partner laboratori
gener revenu consum consum
revenu grew quarter contribut array consum
look back increas instal base instrument market consum
pull follow servic revenu revenu grew y/i growth
servic y/i off-set declin microarray servic y/i
mix revenu instrument vs recur
gross margin declin y/i driven product mix lower margin within
servic busi compani non-gaap gross margin y/i
gross margin expect slightli keep mind
better margin consum revenu grew y/i revenu compar
instrument growth revenu ebitda margin
 ex-comp increas y/i revenu sg ex-comp
increas y/i revenu put togeth total oper
expens sg stock-bas comp increas y/i revenu
helix account sg percentag revenu
non-gaap sg revenu
non-gaap ep decreas y/i top line perform y/i
off-set margin declin higher share count compani tax declin
ep came estim addit
ep impact dilut helix quarter independ tax benefit
quarterli non-gaap ep y/i growth
y/i growthnon-gaap epsepsy/i growth barclay illumina inc
estestestestestestestestincom statement growth growth growth growth growth growth y/i growth product revenu ex product revenu inc product revenu inc servic servic gross gross margin inc gross margin inc growth gener growth base sg stock base ebitda growth oper incom ebit growth invest debt expens pre-tax pre-tax growth incom tax non-control interest net adj net growth growth net net barclay illumina inc
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
